AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELIX PHARMACEUTICALS LTD

25.260

+0.6802.77%

Volume:864.97K

Turnover:21.74M

Market Cap:8.55B

PE:174.69

High:25.380

Open:24.880

Low:24.610

Close:24.580

Loading ...

Overview Company News Filings

ASX Preview: Australian Shares to Open Higher After Wall Street Advances on Trade Hopes

MT Newswires Live

Telix Reports US$186M Q1 Revenue, up 62% YoY

THOMSON REUTERS

Press Release: Telix Reports US$186M Q1 Revenue, Up 62% YOY

Rpt-Telix Pharmaceuticals Ltd - FY 2025 Guidance Reaffirmed

THOMSON REUTERS

Corrected-Telix Pharmaceuticals - Q1 2025 Unaudited Revenue of $186 Mln (Corrects Currency to $ From a$)

THOMSON REUTERS

BRIEF-Telix Pharmaceuticals Posts Q1 2025 Unaudited Revenue Of $186 Million

Telix Pharmaceuticals - Q1 2025 Unaudited Revenue of a$186 Mln

THOMSON REUTERS

Invest $10,000 in these fantastic ASX growth shares

Telix Pharmaceuticals' Potential Brain Cancer Treatment Shows 'Encouraging' Preliminary Results in Study

MT Newswires Live

Telix Reports No Serious Adverse Events Reported in Brain Cancer Combination Therapy Candidate Study

MT Newswires Live

Telix Pharmaceuticals' Prostate Cancer Imaging Agent Illuccix Gets Marketing Authorization in Sweden

MT Newswires Live

5 top ASX 200 stocks that brokers rate as buys after the market selloff

Illuccix® Prostate Cancer Psma-Pet Imaging Agent Approved in Sweden

THOMSON REUTERS

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

ASX Midday Sector Update: Financial Stocks Flat, Healthcare Sector Falls

MT Newswires Live

Telix Pharmaceuticals Taps Cardinal Health as Distributor of Prostate Cancer Imaging Agent Gozellix

MT Newswires Live

Telix Selects Cardinal Health for Commercial Distribution of Gozellix in the US

MT Newswires Live

Telix Pharmaceuticals Limited -Selects Cardinal Health as Distributor for Gozellix in U.S.

THOMSON REUTERS

BUZZ-Australia's Telix Pharmaceuticals jumps; UBS says shares undervalued

Telix Looks Materially Undervalued Given Pipeline -- Market Talk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":25.26,"timestamp":1752819120000,"preClose":24.58,"halted":0,"volume":864974,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338382614,"eps":0.1446,"marketStatus":"Market Closed","change":0.68,"latestTime":"07-18 16:12:00 AEST","open":24.88,"high":25.38,"low":24.61,"amount":21741048,"amplitude":0.031326,"askPrice":25.3,"askSize":34294,"bidPrice":25.19,"bidSize":3759,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1753056000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":24.58,"openAndCloseTimeList":[[1752796800000,1752818400000]],"volumeRatio":0.9092072986915257,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":0.9092072986915257,"shares":338382614,"dividePrice":0,"high":25.38,"amplitude":0.031326,"preClose":24.58,"low":24.61,"week52Low":17.03,"pbRate":"15.04","psRate":"10.91","week52High":31.97,"institutionHeld":0,"latestPrice":25.26,"committee":-0.802433,"eps":0.1446,"divideRate":0,"volume":864974,"delay":0,"ttmEps":0.1446,"open":24.88,"prevYearClose":24.61,"prevWeekClose":24.09,"prevMonthClose":24.42,"prevQuarterClose":24.42,"fiveDayClose":24.09,"twentyDayClose":24.92,"sixtyDayClose":28.32},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529956654","title":"ASX Preview: Australian Shares to Open Higher After Wall Street Advances on Trade Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=2529956654","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529956654?lang=en_us&edition=fundamental","pubTime":"2025-04-23 05:52","pubTimestamp":1745358758,"startTime":"0","endTime":"0","summary":"Australian shares are poised to open higher Wednesday following Wall Street's gains as a top US official signalled hopes for a de-escalation in Washington's trade war with Beijing.The S&P Global Flash Composite PMI is slated for release at 9 am Sydney time.Overnight, the Nasdaq Composite and the Dow Jones Industrial Average rose 2.7% each, while the S&P 500 finished 2.5% higher.In a closed-door meeting on Tuesday, US Treasury Secretary Scott Bessent said the trade war with China will likely de-escalate in the \"very near future\" and that neither Washington nor Beijing \"thinks the status quo is sustainable,\"  CNBC reported, citing an anonymous person who was present at the gathering.In corporate news, Santos  received final environmental approval from Australia's offshore energy regulator for its AU$5.8 billion Barossa gas project, paving the way for first gas in the third quarter of the year, according to a Tuesday report by The Australian, citing the company.Elsewhere, Telix Pharmaceut","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7142","BK7067","STO.AU","XJO.AU","XKO.AU","BK7507","XAO.AU","TLX.AU"],"gpt_icon":0},{"id":"2529334431","title":"Telix Reports US$186M Q1 Revenue, up 62% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2529334431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529334431?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:17","pubTimestamp":1745309829,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA2DWPXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2529341344","title":"Press Release: Telix Reports US$186M Q1 Revenue, Up 62% YOY","url":"https://stock-news.laohu8.com/highlight/detail?id=2529341344","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529341344?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:17","pubTimestamp":1745309820,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025  -- Telix Pharmaceuticals Limited  today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 . All figures are in $US unless stated otherwise.-- Q1 2025 unaudited revenue of approximately $186 million represents an. increase of 62% over the prior year corresponding quarter (Q1 2024:. -- $151 million from global sales of Illuccix, up 35% over the. -- $33 million from RLS Radiopharmacies  since the acquisition. -- Revenue guidance is expected to be updated at the appropriate time,following and subject to reimbursement for Gozellix in the United. expecting a year-over-year increased investment range for FY 2025 of 20%. -- ProstACT Global, the Phase 3 trial of TLX591 (177Lu-rosopatamab. tetraxetan), Telix's prostate cancer therapy candidate, continues to. recruit and remains on track to deliver a Part 1 readout (safety and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Press Release: Telix Reports US$186M Q1 Revenue, Up 62% YOY","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU"],"gpt_icon":0},{"id":"2529831076","title":"Rpt-Telix Pharmaceuticals Ltd - FY 2025 Guidance Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2529831076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529831076?lang=en_us&edition=fundamental","pubTime":"2025-04-22 15:07","pubTimestamp":1745305630,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL8N3R008N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2529754310","title":"Corrected-Telix Pharmaceuticals - Q1 2025 Unaudited Revenue of $186 Mln (Corrects Currency to $ From a$)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529754310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529754310?lang=en_us&edition=fundamental","pubTime":"2025-04-22 15:07","pubTimestamp":1745305630,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL8N3R008N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2529431005","title":"BRIEF-Telix Pharmaceuticals Posts Q1 2025 Unaudited Revenue Of $186 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2529431005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529431005?lang=en_us&edition=fundamental","pubTime":"2025-04-22 15:07","pubTimestamp":1745305630,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Posts Q1 2025 Unaudited Revenue Of $186 MillionApril 22 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:Q1 2025 UNAUDITED REVENUE OF $186 MILLIONFY 2025 GUIDANCE REAFFIRMEDFurther company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nL8N3R008N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU"],"gpt_icon":0},{"id":"2529101733","title":"Telix Pharmaceuticals - Q1 2025 Unaudited Revenue of a$186 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2529101733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529101733?lang=en_us&edition=fundamental","pubTime":"2025-04-22 15:02","pubTimestamp":1745305371,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R0037:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2529357815","title":"Invest $10,000 in these fantastic ASX growth shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2529357815","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529357815?lang=en_us&edition=fundamental","pubTime":"2025-04-22 06:45","pubTimestamp":1745275500,"startTime":"0","endTime":"0","summary":"If you are lucky enough to have $10,000 to invest and also have a penchant for ASX growth shares, then read on!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/22/invest-10000-in-these-fantastic-asx-growth-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7049","TPW.AU","BK7067","NXT.AU","BK7043","BK7107","TLX.AU","BK7503"],"gpt_icon":0},{"id":"2527825540","title":"Telix Pharmaceuticals' Potential Brain Cancer Treatment Shows 'Encouraging' Preliminary Results in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527825540","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527825540?lang=en_us&edition=fundamental","pubTime":"2025-04-16 15:32","pubTimestamp":1744788751,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Tuesday it received \"encouraging\" preliminary results from an eight-patient phase 2 study of TLX101 in combination with radiation therapy as a potential treatment for recurrent high-grade glioma, a form of brain cancer.The company said the study showed a median overall survival of 12.4 months for patients treated with the TLX101-radiation therapy combo compared with 9.9 months for patients treated with radiation alone.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","BK4139","TLX.AU"],"gpt_icon":0},{"id":"2527402798","title":"Telix Reports No Serious Adverse Events Reported in Brain Cancer Combination Therapy Candidate Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527402798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527402798?lang=en_us&edition=fundamental","pubTime":"2025-04-16 09:55","pubTimestamp":1744768556,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said that its Phase 2 IPAX-Linz study of drug candidate TLX101, in combination with external beam radiation therapy , was well tolerated and showed no serious adverse events in patients with brain cancer, according to a Wednesday filing with the Australian bourse.The study indicated a median overall survival of 12.4 months from treatment initiation, and 32.2 months from diagnosis, the company said.The company has submitted an ethics approval request for a registration-enabling study of TLX101 in recurrent brain cancer, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2527419474","title":"Telix Pharmaceuticals' Prostate Cancer Imaging Agent Illuccix Gets Marketing Authorization in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419474","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527419474?lang=en_us&edition=fundamental","pubTime":"2025-04-15 23:23","pubTimestamp":1744730601,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Tuesday its prostate cancer imaging agent Illuccix has received marketing authorization from Sweden's Medical Products Agency.This approval came after recent authorizations in Norway and Denmark, the company said.Price: 16.86, Change: +0.03, Percent Change: +0.15","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX.AU","BK7067","TLX"],"gpt_icon":0},{"id":"2527448763","title":"5 top ASX 200 stocks that brokers rate as buys after the market selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=2527448763","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527448763?lang=en_us&edition=fundamental","pubTime":"2025-04-15 15:10","pubTimestamp":1744701034,"startTime":"0","endTime":"0","summary":"If you are on the lookout for some investment ideas, then it could be worth checking out what analysts saying. Listed below are five ASX 200 stocks that leading brokers currently rate as buy. Here's w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/15/5-top-asx-200-stocks-that-brokers-rate-as-buys-after-the-market-selloff/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7044","BK7511","BK7501","MQG.AU","RMD.AU","BK7016","BK7067","TLX.AU","JHX.AU","BK7046","XRO.AU","BK7007","BK7503","WTC.AU"],"gpt_icon":1},{"id":"2527432489","title":"Illuccix® Prostate Cancer Psma-Pet Imaging Agent Approved in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2527432489","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527432489?lang=en_us&edition=fundamental","pubTime":"2025-04-15 14:17","pubTimestamp":1744697826,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA7DKSRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2527115590","title":"All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2527115590","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527115590?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:00","pubTimestamp":1744646410,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Telix Pharmaceuticals Limited , as it has been recently upgraded to a Zacks Rank #2 . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for Telix Pharmaceuticals Limited is essentially a positive comment on its earnings outlook that could have a favorable impact on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-telix-pharmaceuticals-limited-tlx-160010240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLX","TLX.AU"],"gpt_icon":0},{"id":"2526809186","title":"ASX Midday Sector Update: Financial Stocks Flat, Healthcare Sector Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2526809186","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526809186?lang=en_us&edition=fundamental","pubTime":"2025-04-09 11:34","pubTimestamp":1744169679,"startTime":"0","endTime":"0","summary":"Financial sector stocks were flat on midday Wednesday, with the rest of the sectors on the Australian bourse trading in the red.Regal Partners (ASX:RPL) said that its funds under management came in at","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX.AU","HCSG","RPL.AU","BK4137","BK7062"],"gpt_icon":0},{"id":"2526820081","title":"Telix Pharmaceuticals Taps Cardinal Health as Distributor of Prostate Cancer Imaging Agent Gozellix","url":"https://stock-news.laohu8.com/highlight/detail?id=2526820081","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526820081?lang=en_us&edition=fundamental","pubTime":"2025-04-09 08:19","pubTimestamp":1744157967,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) named New York Stock Exchange-listed healthcare company Cardinal Health as one of the commercial radiopharmaceutical distributors of its prostate cancer imaging agent, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU1267930227.SGD","LU1880398554.USD","BK4175","TLX.AU","LU0889566641.SGD","LU0154236417.USD","SG9999001440.SGD","LU1267930490.SGD","LU0310799852.SGD","LU0162691827.USD","BK7067","LU0211327993.USD","CAH","LU0310800965.SGD","TLX","LU1267930813.SGD","LU0211328371.USD","LU1571399168.USD","LU0006061336.USD","BK4588","LU0072461881.USD","LU1880398471.USD","LU0128525689.USD","LU0052756011.USD","LU0792757196.USD"],"gpt_icon":0},{"id":"2525984908","title":"Telix Selects Cardinal Health for Commercial Distribution of Gozellix in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2525984908","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525984908?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:08","pubTimestamp":1744110494,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Tuesday that it has selected Cardinal Health (CAH) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix for the treatmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1571399168.USD","LU0310799852.SGD","LU0052756011.USD","SG9999001440.SGD","LU0211327993.USD","LU1880398471.USD","LU1267930227.SGD","CAH","LU0162691827.USD","BK7067","LU0154236417.USD","BK4139","TLX","BK4588","LU0128525689.USD","LU1267930813.SGD","LU1267930490.SGD","BK4585","LU0889566641.SGD","LU1880398554.USD","LU0072461881.USD","TLX.AU","BK4175","LU0006061336.USD","LU0792757196.USD","LU0211328371.USD","LU0310800965.SGD"],"gpt_icon":0},{"id":"2525201862","title":"Telix Pharmaceuticals Limited -Selects Cardinal Health as Distributor for Gozellix in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525201862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525201862?lang=en_us&edition=fundamental","pubTime":"2025-04-08 18:31","pubTimestamp":1744108307,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM16I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1571399168.USD","LU0310799852.SGD","LU0052756011.USD","SG9999001440.SGD","LU0211327993.USD","LU1880398471.USD","LU1267930227.SGD","CAH","LU0162691827.USD","BK7067","LU0154236417.USD","BK4588","LU0128525689.USD","LU1267930813.SGD","LU1267930490.SGD","BK4585","LU0889566641.SGD","LU1880398554.USD","LU0072461881.USD","TLX.AU","BK4175","LU0006061336.USD","LU0792757196.USD","LU0211328371.USD","LU0310800965.SGD"],"gpt_icon":0},{"id":"2525183324","title":"BUZZ-Australia's Telix Pharmaceuticals jumps; UBS says shares undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2525183324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525183324?lang=en_us&edition=fundamental","pubTime":"2025-04-08 13:00","pubTimestamp":1744088417,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals jumps; UBS says shares undervalued** Telix Pharmaceuticals TLX.AX jumps as much as 7.4% to A$24.87; marks biggest intraday pct gain since February 21** Stock declined for last five straight sessions, hurt by soured investor sentiment amid global trade war** UBS says shares look undervalued, given that co is profitable and manufactures its U.S.-sold products within the country and hence impacted minimally by tariffs** YTD, TLX up 0.7%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nL3N3QM0G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2525381078","title":"Telix Looks Materially Undervalued Given Pipeline -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2525381078","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525381078?lang=en_us&edition=fundamental","pubTime":"2025-04-08 12:33","pubTimestamp":1744086780,"startTime":"0","endTime":"0","summary":"0433 GMT - Telix Pharmaceuticals' Australia-listed stock looks materially undervalued to UBS analysts given the strength of its therapeutic pipeline. They point out that the stock has been trading below what they calculate to be the combined valuation of Telix's Illuccix, Gozellix, Pixclara and Zircaix products, all of which are either approved for use in the U.S. or stand a good chance of being approved. The scientific and clinical failure that the valuation implies is highly unlikely, they write in a note to clients. With no obvious need to raise external funds and a U.S. manufacturing base, UBS keeps its buy rating and A$36.00 target price on Telix. Shares are up 7.0% at A$24.78. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null},{"date":"2023-08-23","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692748800000,"name":null,"time":"","dateTimestamp":1692712800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[]}}